Complement C3b/C4b receptor 1-like (CR1L) is an emerging complement regulatory target playing a pivotal role in immune evasion and autoimmune homeostasis.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CR1L drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CR1L ECD-Fc Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View CR1L Products |
| Gene Delivery | CR1L Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. Ideal for flow cytometry and CDC assays. |
View CR1L Products |
| Benchmark Ab | Anti-CR1L Recombinant Antibody Recombinant positive control matching reference sequences for assay validation. |
View CR1L Products |
| Validator | CR1L siRNA Set For target knockdown validation in functional assays. |
View CR1L Products |
| Related Target A | CR1 (CD35) High homology complement receptor. Essential for selectivity screening and counter-screening. |
View CR1 Products |
| Related Target B | CD55 (DAF) Synergistic complement regulator. Co-inhibition enhances complement-dependent cytotoxicity (CDC) in tumors. |
View CD55 Products |
| Related Target C | CD59 Terminal complement pathway inhibitor. Combined targeting overcomes tumor resistance to therapeutic antibodies. |
View CD59 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity against high-homology CR1 | Recombinant CR1L and CR1 control proteins strictly verified by mass spectrometry and sequence analysis. |
| Conformational preservation for binding assays | HEK293 expression system ensures native post-translational modifications and folding. |
| Lack of reliable screening controls | Sequence-verified clinical benchmark antibodies included in the portfolio. |
| False positives in cell-based assays | Validated siRNA sets included to confirm target-specific knockdowns. |
Live CR1L R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CR1L therapeutics is intensifying, with major players shifting focus from traditional mAbs to bispecific antibodies and antibody-drug conjugates (ADCs) designed to modulate the complement microenvironment. As first-generation complement-targeting therapies reach the clinic, the next wave of R&D is targeting CR1L to overcome complement-dependent cytotoxicity (CDC) resistance in hematological and solid tumors.
CR1L (Complement C3b/C4b receptor 1-like) acts as a key membrane-bound complement regulatory protein (mCRP). By binding C3b and C4b, CR1L accelerates the decay of C3/C5 convertases, shielding target cells from complement-mediated destruction. In oncology, tumor cells upregulate CR1L to evade mAb-induced CDC. Consequently, blocking CR1L represents a major therapeutic avenue to sensitize tumors to established immunotherapies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (mAbs) | Biotech Innovators, Academic Medical Centers | Autoimmune Diseases, Systemic Lupus Erythematosus (SLE) | Ligand-blocking assays (Requires high-purity ECD-Fc to study C3b/C4b interaction) |
| Bispecific Antibodies (BsAbs) | Oncology-focused Biopharma | B-cell Malignancies, Solid Tumors | Dual-targeting validation (Requires stable cell lines via Lentivirus transfection) |
| Combination Therapies (with Rituximab/Trastuzumab) | Global Pharmaceutical Corporates | Refractory Lymphoma, HER2+ Breast Cancer | CDC enhancement assays (Requires sequence-verified benchmark antibodies as positive controls) |